Early adoption of anti-Covid pharmacotherapies among veterans with mild to moderate Covid

JAMA Network

About The Study: In this study of more than 111,000 veterans who tested positive for SARS-CoV-2 during January and February 2022 when supply of outpatient COVID-19 pharmacotherapies was limited, prescription of these pharmacotherapies was underused, and many veterans with risk factors for severe COVID-19 did not receive treatment. Veterans from minority racial and ethnic groups were less likely to receive any pharmacotherapy.

Authors: Kristina L. Bajema, M.D., M.Sc., of the Veterans Affairs Portland Health Care System in Portland, Oregon, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2022.41434)

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.